Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Precision psychiatry is an approach designed to improve diagnosis and treatment of mental disorders by leveraging biological insights and developing innovative, mechanism-based treatment strategies unconstrained by current diagnostic boundaries. At its core, precision psychiatry aims to pinpoint the underlying neurobiological mechanisms responsible for the emergence and persistence of symptoms of mental health conditions. This approach strives to create diagnostic tools and therapies targeting these mechanisms, potentially addressing previously resistant aspects of mental health conditions by providing more precise symptom management and possibly altering the disease trajectory. Although still in its nascent stages, the realization of precision psychiatry will result in a more refined and biology-informed diagnostic system for mental disorders, requiring significant adaptations for clinicians, industry, patients and regulators. Identifying, validating and applying both fluid and functional biomarkers are critical steps in the development, testing and application of new precision psychiatry diagnostics and treatments. As part of the 2025 Precision Psychiatry Roadmap initiative meeting in Frankfurt, experts came together to present and discuss the current status of biomarker identification and validation, patient subtyping, and targeted interventions for stratified patient groups. This report features lecture summaries, meeting outcomes, and recommendations from both online and in-person audiences. In general, the recommendations emphasize standardization, collaboration, clinical implementation, digital innovation, long-term planning, and, importantly, patient engagement, as key priorities for advancing precision psychiatry. Despite existing challenges, there is strong optimism for the future of precision psychiatry, with continuous efforts to refine diagnostic tools and treatment strategies.

Authors

Institutions

Publication Details

Journal
European Neuropsychopharmacology
Published
2026-01-15
DOI
https://doi.org/10.1016/j.euroneuro.2026.112762
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Gitte M. Knudsen, Wayne C. Drevets, Elizabeth M. Tunbridge, Rouba Kozak et al.
European Neuropsychopharmacology
Treatment of Major Depression
article

Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Gitte M. Knudsen, Wayne C. Drevets, Elizabeth M. Tunbridge, Rouba Kozak, Martien J. Kas, Derek L. Buhl, Michael Sand, Brenda W.J.H. Penninx, Frank J. Padberg, Kim Q. Do, Andreas Reif, Peter Falkai, Maria A. Oquendo, Carol Tamminga, Nikolaos Koutsouleris
article en

Abstract

Precision psychiatry is an approach designed to improve diagnosis and treatment of mental disorders by leveraging biological insights and developing innovative, mechanism-based treatment strategies unconstrained by current diagnostic boundaries. At its core, precision psychiatry aims to pinpoint the underlying neurobiological mechanisms responsible for the emergence and persistence of symptoms of mental health conditions. This approach strives to create diagnostic tools and therapies targeting these mechanisms, potentially addressing previously resistant aspects of mental health conditions by providing more precise symptom management and possibly altering the disease trajectory. Although still in its nascent stages, the realization of precision psychiatry will result in a more refined and biology-informed diagnostic system for mental disorders, requiring significant adaptations for clinicians, industry, patients and regulators. Identifying, validating and applying both fluid and functional biomarkers are critical steps in the development, testing and application of new precision psychiatry diagnostics and treatments. As part of the 2025 Precision Psychiatry Roadmap initiative meeting in Frankfurt, experts came together to present and discuss the current status of biomarker identification and validation, patient subtyping, and targeted interventions for stratified patient groups. This report features lecture summaries, meeting outcomes, and recommendations from both online and in-person audiences. In general, the recommendations emphasize standardization, collaboration, clinical implementation, digital innovation, long-term planning, and, importantly, patient engagement, as key priorities for advancing precision psychiatry. Despite existing challenges, there is strong optimism for the future of precision psychiatry, with continuous efforts to refine diagnostic tools and treatment strategies.

European NeuropsychopharmacologyVol. 105
Johnson & Johnson (United States) (US), Boehringer Ingelheim (Germany) (DE), University of Groningen (NL), Foundation for the National Institutes of Health (US), Copenhagen University Hospital (DK), LMU Klinikum (DE), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Precision for Medicine (United States) (US), Max Planck Institute of Psychiatry (DE), Amsterdam University Medical Centers (NL), University of Pennsylvania (US), Ludwig-Maximilians-Universität München (DE), Vrije Universiteit Amsterdam (NL), The University of Texas Southwestern Medical Center (US), University of Lausanne (CH)
European College of Neuropsychopharmacology
Industry, innovation and infrastructure
Openalex Percentile: Top 85%
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.